Therapeutic agent

Details Therapeutic agent Therapeutic agent

2006-05-16

2006-05-16

Meller, Michael (Department: 1655)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07045499

ABSTRACT:
The invention relates to an agent for the depletion of unwanted proteins from plasma comprising a plurality of ligands covalently co-linked to produce a complex with a plurality of proteins whierein at least two of the ligands are capable of being bound by ligand binding sites on the proteins and wherein the non-protein access agent excludes certain D-proline derivatives.

REFERENCES:
patent: 4783480 (1988-11-01), Wakatsuka et al.
patent: 4895872 (1990-01-01), Nitecki et al.
patent: 6103910 (2000-08-01), Hertel et al.
patent: 6365570 (2002-04-01), Van Kessel et al.
patent: 0915088 (1999-05-01), None
patent: WO 9746098 (1997-12-01), None
patent: WO 98/50420 (1998-11-01), None
Iverson, “Amyloid diseases: Small drugs lead the attack,” Nature, p. 414: 231-233, (2002).
Borman, “Chemistry Highlights 2002, Medicinal and Combinatorial Chemistry,” Chem. Eng. News, p. 80: 37-38, (2002).
PCT search report PCT/GB 02/03504.
Lindorfer et al., “A bispecific dsDNAXmonoclonal antibody construct for clearance af anti-dsDNA IGG in systemic lupus erythematosus”,J. Immunol. Methods248, 125-138, 2001.
Riedstra et al., “Study of an anti-human transthyretin immunoadsorbent—influence of coupling chemistry on binding capacity and ligand leakage”,J. Chromatogr. B: Biomedical Sciences&Applications.705(2), 213-222, 1998.
Paul et al., “Identification of optimal anion spacing for anti-HIV activity in a series of cosalane tetracarboxylates”,Bioorg. Med. Chem. Lett.10(18), 2149-2152, 2000.
Cleaveland et al., “Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program”,Biochem. Pharmacol.49(7), 947-954, 1995.
Purkey et al., “Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma”,Proc. Natl. Acad. Sci. USA98(10), 5566-5571, 2001.
Pepys et al., “Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis”,Nature417, 254-259, 2002.
Hind et al., “Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits”,Lancet, 376-378, 1984.
Tennent et al., “Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis”,Proc. Natl. Acad. Sci. USA92, 299-4303, 1995.
Pepys et al., “Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy”,The Nature and Origin of Amyloid Fibrils, 73-89, 1996.
Pepys et al., “Amyloid P component. A critical review.”,Int. J. Exp. Clin. Invest.4, 274-295, 1997.
Pepys, “C-reactive protein and amyloidosis: from protein to drugs?”, The Lumleian Lecture, 397-414.
Nelson et al., “Serum amyloid P component in chronic renal failure and dialysis”,Clinica Chimica Acta200, 191-200, 1991.
Booth et al., “Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis”,Nature385, 787-793, 1997.
Pepys et al., “Human lysozyme gene mutations cause hereditary systemic amyloidosis”,Nature362, 553-557, 1993.
Holmgren et al., Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30),Clin. Genet.40, 242-246, 1991.
Pepys et al., “Isolation of amyloid P component (Protein AP) from normal serum as a calcium-dependent binding protein”,Lancet, 1029-1031, 1977.
Pontet et al., “One step preparation of both human C-creative protein and Cit”,FEBS Letters88(2), 172-175, 1978.
Hind et al., “Binding specificity of serum amyloid P component for the pyruvate acetal of galactose”,J. Exp. Med.159, 1058-1069, 1984.
Emsley et al., “Structure of pentameric human serum amyloid P component”,Nature367, 338-345, 1994.
Hohenester et al., “Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP”,J. Mol. Biol.269, 570-578, 1997.
Ashton et al., “Pentameric and decameric structures in solution of serum amyloid P component by X-ray and neutron scattering and molecular modelling analyses”,J. Mol. Biol.272, 408-422, 1997.
Baltz et al., “Calcium-dependent aggregation of human serum amyloid P component”,Biochim. Biophys. Acta701, 229-236, 1982.
Booth et al., “Analysis of autoaggregation and ligand binding sites of serum amyloid P component by in vitro mutagenesis”,Amyloid and Amyloidosis 1998, 23-25, 1998.
Hutchinson et al., “Human serum amyloid P component is a single uncomplexed pentamer in whole serum”,Mol. Med.6(6), 482-493, 2000.
Hawkins et al., “Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis”,J. Clin. Invest.86, 1862-1869, 1990.
Hutchinson et al., “The petraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by hepatocytes in vivo”,J. Clin. Invest.94, 1390-1396, 1994.
Pepys et al., “Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure”,Proc. Natl. Acad. Sci. USA91, 5602-5606, 1994.
Holmgren et al., “Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis”,Lancet, 1113-1116, 1993.
Klabunde et al., “Rational design of potent human transthyretin amyloid disease inhibitors”,Nature Struct. Biol.7(4), 312-321, 2000.
Solomon et al., Heterobifunctional Multivalent Inhibitor-Adaptor Medietes Specific Aggregates between Shiga Toxin and a Pentraxin Organic Letters, American Chemical Society, Vol. 7 (No. 20). pp. 4369-4372.

Affiliated with

Also associated with

Rating

Therapeutic agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3536920